Algert Global LLC Has $996,000 Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Algert Global LLC grew its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 248.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,487 shares of the company's stock after acquiring an additional 50,990 shares during the period. Algert Global LLC owned about 0.07% of Day One Biopharmaceuticals worth $996,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Bayesian Capital Management LP acquired a new position in shares of Day One Biopharmaceuticals during the 1st quarter worth approximately $221,000. SG Americas Securities LLC acquired a new position in shares of Day One Biopharmaceuticals in the second quarter valued at $113,000. SteelPeak Wealth LLC bought a new position in shares of Day One Biopharmaceuticals in the second quarter valued at about $218,000. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Day One Biopharmaceuticals by 8.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 64,359 shares of the company's stock worth $887,000 after buying an additional 5,070 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter worth about $994,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on DAWN. HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Needham & Company LLC reissued a "buy" rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. JPMorgan Chase & Co. decreased their price objective on Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating on the stock in a report on Tuesday, August 6th. Finally, TD Cowen raised Day One Biopharmaceuticals to a "strong-buy" rating in a report on Monday, November 4th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $35.71.

Day One Biopharmaceuticals Stock Up 1.5 %

Shares of NASDAQ:DAWN traded up $0.21 during trading on Friday, reaching $13.93. 450,390 shares of the company traded hands, compared to its average volume of 953,851. Day One Biopharmaceuticals, Inc. has a 52 week low of $11.30 and a 52 week high of $18.07. The firm has a market capitalization of $1.40 billion, a PE ratio of -13.52 and a beta of -1.51. The company's 50 day moving average is $14.32 and its two-hundred day moving average is $14.16.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.58. The firm had revenue of $93.76 million during the quarter, compared to the consensus estimate of $15.05 million. During the same period in the prior year, the business earned ($0.54) earnings per share. As a group, research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the business's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $16.10, for a total transaction of $161,000.00. Following the completion of the transaction, the insider now owns 1,057,535 shares of the company's stock, valued at approximately $17,026,313.50. The trade was a 0.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 51,745 shares of company stock worth $775,867 over the last three months. Insiders own 8.40% of the company's stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.